Full Press Release Details
Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical's Scientific Advisory Board
Mass., June 7, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities
as Giora Weisz, MD joined the Company's Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiologist
and clinical researcher who has pioneered novel robotic-enhanced coronary interventions, as well as navigation and positioning technologies.
His areas of expertise include cardiac catheterization, coronary artery disease and diagnostic angiography, which make his assistance
an invaluable asset to Microbot as it continues to develop the LIBERTYTM Robotic System.
Weisz performed the Corindus Vascular Robotics' (acquired by Siemens Healthineers) First-in-Human (FIH) clinical trial to evaluate
the safety and technical efficacy of Corindus' CorePath system in delivering and manipulating coronary guidewires and stent/balloon
systems in PCI procedures. He was also the principal investigator of the multi-center pivotal study leading to the FDA approval of the
system. He was the first to use this system on patients in the U.S. Dr. Weisz is often invited to speak about robotic-enhanced interventions
in national and international medical conferences.
Weisz is an Associate Professor of Medicine at Columbia University Medical Center, Director of Interventional Cardiology at the New York-Presbyterian
Hudson Valley Hospital, and a member of the faculty of the Center of Interventional Vascular Therapy at Columbia University Medical Center.
He is also a faculty member at the Cardiovascular Research Foundation in New York. Dr. Weisz graduated from the Hebrew University-Hadassah
Medical School in Jerusalem, Israel and completed his residency in internal medicine and cardiology fellowship at the Carmel Medical
Center in Haifa, Israel. His training in interventional cardiology was completed at Lenox Hill Hospital in New York. As a practicing
interventional cardiologist, Dr. Weisz has particular interest in current and innovative technologies in cardiovascular medicine.
is exciting to continue attracting leading experts in their fields, including Dr. Weisz, who have experience in the endovascular robotic
space and see the value that our LIBERTY system can add to their practice," commented Harel Gadot, CEO, President and Chairman.
"With his extensive experience, Dr. Weisz will be a welcome addition to our already impressive SAB. Specifically, he will be intimately
involved in the advancement of our LIBERTY Robotic System as we aim to further enhance its capabilities to address the sizeable cardiac
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms
provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for
patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future
financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot
Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed
by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the
Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such
as "will," "believes," "plans," "anticipates," "expects" and "estimates")
should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without
limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization
of potential products, including LIBERTY, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports
filed with the Securities and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to
be filed with the SEC, which are or will be available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent
or obligation to update these forward-looking statements, except as required by law.